TruScreen Group Limited

Equities

TRU

NZTRUE0001S7

Advanced Medical Equipment & Technology

End-of-day quote New Zealand S.E. Other stock markets 06:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
0.018 ^NZD	0.00%		0.00%	-21.74%

Jul. 08	New Zealand Shares Fall Ahead of Central Bank Policy Meeting; TruScreen Debuts in Vietnam	MT
Jul. 08	TruScreen Debuts in Vietnam with NZ$100,000 Order for Cervical Cancer Screening Devices	MT

TruScreen : Tackling cervical cancer through tech innovation and global expansion

December 09, 2021 at 05:52 pm EST

TruScreen Group Limited's (NZX/ASX: TRU) CEO Juliet Hull sits down with MarketLit's host Lelde Smits to discuss the TruScreen technology, eliminating cervical cancer and TruScreen's 2022 outlook.

Attachments

Original Link
Original Document
Permalink

Disclaimer

TruScreen Limited published this content on 10 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2021 22:51:05 UTC.

Latest news about TruScreen Group Limited

New Zealand Shares Fall Ahead of Central Bank Policy Meeting; TruScreen Debuts in Vietnam	Jul. 08	MT
TruScreen Debuts in Vietnam with NZ$100,000 Order for Cervical Cancer Screening Devices	Jul. 07	MT
TruScreen Group Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 30	CI
Truscreen's Fiscal Year 2024 Loss Widens	May. 30	MT
Truscreen Group Raises Additional NZ$520,000 via Share Placement; Shares Jump 5%	Mar. 12	MT
New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire	Mar. 07	MT
TruScreen to Start Clinical Evaluation Trials for Cancer Screening Device	Mar. 07	MT
Truscreen Close to Raising NZ$500,000	Mar. 04	MT
New Zealand Shares Close the Week in the Green; Port of Tauranga’s Fiscal H1 Revenue Falls	Feb. 22	MT
Truscreen's CEO Resigns	Feb. 22	MT
TruScreen Group Limited Announces CEO Changes	Feb. 22	CI
Truscreen Group to Offer Pro-Rata Renounceable Rights Issue; Shares Plunge 11%	Feb. 11	MT
TruScreen Secures Reimbursement Approval in Saudi Arabia for Cervical Cancer Screening Device; Shares Rise 4%	Feb. 11	MT
Truscreen Secures Regulatory Approval to Expand Use of Cancer Screening Device in Mexico; Shares Rise 4%	Feb. 06	MT
Truscreen Group Limited Receives Approval in Mexico to Enter Public Health Sector	Feb. 06	CI
TruScreen's Nine-Month Revenue Surges 34%	Jan. 25	MT
Truscreen Group Limited Announces Sales Results for the Nine Months Ended 31 December 2023	Jan. 24	CI
New Zealand Bourse Regulator Slaps TruScreen a Fine on Audit Committee Breach	Jan. 02	MT
TruScreen Wins Polish Start-Up Challenge; Shares Rise 5%	Dec. 13	MT
New Zealand Shares Rebound on Wednesday, Air New Zealand Expects Fiscal H1 Earnings to be on the Lower End of Guidance	Dec. 12	MT
TruScreen's Diagnostic Device Lands Spot in Vietnam Health Ministry's Approved Technical List; Shares Rise 5%	Dec. 12	MT
TruScreen Secures Purchase Order from Zimbabwe	Nov. 05	MT
TruScreen Group Limited Confirms Receipt of Further Purchase Order from Zimbabwe for SUS	Nov. 05	CI
TruScreen Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 05	CI
Truscreen Logs 33% Growth in Fiscal H1 Revenue	23-10-12	MT

Chart TruScreen Group Limited

Duration

Period

More charts

Company Profile

Truscreen Group Limited is a New Zealand-based medical device company. The Company is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Companyâs cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. It also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-11-26 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
TRUSCREEN GROUP LIMITED	-21.74%	6.1M
THERMO FISHER SCIENTIFIC	+0.02%	205B
DANAHER CORPORATION	+3.38%	178B
INTUITIVE SURGICAL, INC.	+31.39%	158B
BOSTON SCIENTIFIC CORPORATION	+32.17%	112B
SIEMENS HEALTHINEERS AG	+1.79%	64.58B
EDWARDS LIFESCIENCES CORPORATION	+21.63%	55.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.27%	46.64B
AGILENT TECHNOLOGIES, INC.	-10.26%	36.78B
GE HEALTHCARE TECHNOLOGIES INC.	-1.42%	34.85B

Other Advanced Medical Equipment & Technology